Enzyvant Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

BASEL, Switzerland, Dec. 12, 2018 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing therapies for people with rare diseases, today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston is a veteran biopharmaceutical executive with more than 25 years' experience leading global business and financial operations for start-up, private and public companies.

"George has a tremendous background ideally suited to Enzyvant," said Alvin Shih, M.D., Chief Executive Officer of Enzyvant. "His broad-based experience and excellent track record speak to his ability to bring immense value as we look forward to achieving our near-term milestones, including completion of the rolling RVT-802 BLA filing and initiation of the RVT-801 clinical study." 

"Enzyvant, in its short history, has efficiently acquired and developed two unique pipeline assets – one in late-stage development – with potential to be truly transformative therapies," according to Mr. Elston. "I look forward to helping advance these important therapies toward the market, while building Enzyvant's capability to deliver therapies that address major unmet needs for people with rare diseases and their families."

Mr. Elston most recently served as President and Chief Executive Officer of 2X Oncology, Inc. and was previously the Chief Financial Officer of Juniper Pharmaceuticals, Inc. Currently he is a trustee and Audit Committee Chairman for the Deutsche Bank AG - DBX Trust. Mr. Elston earned his B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant.

About Enzyvant

Enzyvant is a biopharmaceutical company focused on developing innovative treatments for people with rare diseases. Enzyvant has initiated a rolling Biologics License Application submission with the FDA for RVT-802, an investigational tissue-based therapy for the treatment of primary immunodeficiency associated with complete DiGeorge Anomaly. Enzyvant is simultaneously preparing to initiate a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease.

For more information, please visit www.enzyvant.com.  

For Media Inquiries, Please Contact:

Tamara Joseph, General Counsel, [email protected]

­

SOURCE Enzyvant

Related Links

http://www.enzyvant.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED